Archon Biosciences

Antibodies Transformed

Seattle, United States · Founded 2023 · $20.0M raised

Employees
11–50
Founded
2023
Business Model
B2B
Website
archon.bio
Total Funding
$20.0M
Last Round
$20.0M SeedNov 2024
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round for this company. The full record is or through the API.

About

Archon Biosciences is a Seattle-based biotechnology company pioneering computationally designed Antibody Cages (AbCs) to advance drug development. Spun out of the Baker Lab at the University of Washington Institute for Protein Design—the lab whose foundational work was recognized by the 2024 Nobel Prize in Chemistry—Archon directly applies generative protein design to rapidly manufacture a new biologic class. AbCs combine off-the-shelf antibodies with AI-generated protein structures that self-assemble into exquisitely precise nanostructures, providing unique control over biodistribution and target engagement. The company's platform enables rapid exploration of previously intractable drug discovery challenges and is backed by $20M in seed financing led by Madrona Ventures.

Summary

Archon Biosciences is a Biotech company based in Seattle, United States, founded in 2023. It has raised $20.0M in total across 1 round, most recently a $20.0M Seed round in Nov 2024.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedNov 2024
$20.0M

Similar Companies

AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Enveda

Enveda reads and translates nature’s hidden chemistry to accelerate the discovery of better medic...

Boulder, United States201–500Biotech, Artificial Intelligence
Series ETotal funding$1.1BSep 2026
Eikon TherapeuticsIPO

Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...

Hayward, United States201–500Artificial Intelligence, Biotech
Series DTotal funding$1.1BFeb 2025
Xaira Therapeutics

Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intellig...

South San Francisco, United States51–200Artificial Intelligence, Biotech
Series ATotal funding$1.0BApr 2024
Treeline Biosciences

Clinical-stage biopharma developing precision medicines for cancer and other serious diseases usi...

Watertown, United States51–200Biotech, Drug Discovery
Extension RoundTotal funding$821.8MSep 2025

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Archon Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/archon-biosciences"><img src="https://indexed.vc/api/badge/company/archon-biosciences" alt="Archon Biosciences on Indexed.vc" width="260" height="76" /></a>